文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

艾曲泊帕治疗伴血小板减少的低危骨髓增生异常综合征:II期随机安慰剂对照临床试验(EQOL-MDS)的中期结果

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
PubMed 文献 · J Clin Oncol · 2023-06-09

这项多中心、单盲、随机、安慰剂对照II期试验纳入国际预后评分系统低危或中危-1且血小板持续<30×10^3/mm^3的成人MDS患者,比较口服艾曲泊帕与安慰剂。艾曲泊帕组血小板缓解率42.3%(47/111)高于安慰剂组11.1%(6/54),比值比5.9(95%CI 2.3–14.9,P<.001),临床显著出血发生率更低(发生率比0.54,95%CI 0.38–0.75,P=.0002),但3–4级不良事件比例更高(χ2=9.5,P=.002)。

要点

  • 艾曲泊帕组血小板缓解47/111(42.3%) vs 安慰剂组6/54(11.1%),比值比5.9(95%CI 2.3–14.9,P<.001)。
  • 艾曲泊帕组WHO出血评分≥2的临床显著出血发生率比安慰剂组低(发生率比0.54,95%CI 0.38–0.75,P=.0002)。
  • 艾曲泊帕组3–4级不良事件比例高于安慰剂组(χ2=9.5,P=.002),1–2级不良事件频率无差异。

核心结论

  • 艾曲泊帕在伴严重血小板减少的低危MDS中有效且相对安全。

研究设计与样本

  • 多中心、单盲、随机、安慰剂对照II期试验,纳入国际预后评分系统低危或中危-1且血小板持续<30×10^3/mm^3的成人MDS患者。
  • 2011年至2021年筛查325例,随机169例至口服艾曲泊帕(N=112)或安慰剂(N=57),起始剂量50 mg每日一次,最大300 mg,治疗至疾病进展。
  • 主要终点为血小板缓解持续时间(从血小板缓解至失去缓解,即出血/血小板<30×10^3/mm^3或末次观察日期)及长期安全性与耐受性。

主要发现

  • 中位随访25周(IQR 14–68),血小板缓解在艾曲泊帕组为47/111(42.3%),安慰剂组为6/54(11.1%),比值比5.9(95%CI 2.3–14.9,P<.001)。
  • 艾曲泊帕组47例缓解者中12例(25.5%)失去血小板缓解,60个月累计无血小板减少复发生存率为63.6%(95%CI 46.0–81.2)。
  • 临床显著出血(WHO出血评分≥2)在艾曲泊帕组发生率低于安慰剂组(发生率比0.54,95%CI 0.38–0.75,P=.0002)。
  • 1–2级不良事件频率无差异,但艾曲泊帕组3–4级不良事件比例更高(χ2=9.5,P=.002)。
  • 急性髓系白血病演变和/或疾病进展在艾曲泊帕组与安慰剂组均为17%,生存时间无差异。

关键数值与推荐

  • 血小板缓解定义:血小板计数从<30×10^3/mm^3升至≥30×10^3/mm^3且较基线增加至少一倍,无出血,无需血小板输注。
  • 临床显著出血定义为WHO出血评分≥2。
  • 艾曲泊帕起始剂量50 mg每日一次,最大剂量300 mg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. This multicenter trial presents the second-part long-term efficacy and safety results of eltrombopag in patients with low-risk MDS and severe thrombocytopenia. METHODS: In this single-blind, randomized, placebo-controlled, phase-II trial of adult patients with International Prognostic Scoring System low- or intermediate-1-risk MDS, patients with a stable platelet (PLT) count (<30 × 103/mm3) received eltrombopag or placebo until disease progression. Primary end points were duration of PLT response (PLT-R; calculated from the time of PLT-R to date of loss of PLT-R, defined as bleeding/PLT count <30 × 103/mm3 or last date in observation) and long-term safety and tolerability. Secondary end points included incidence and severity of bleeding, PLT transfusions, quality of life, leukemia-free survival, progression-free survival, overall survival and pharmacokinetics. RESULTS: From 2011 to 2021, of 325 patients screened, 169 patients were randomly assigned oral eltrombopag (N = 112) or placebo (N = 57) at a starting dose of 50 mg once daily to maximum of 300 mg. PLT-R, with 25-week follow-up (IQR, 14-68) occurred in 47/111 (42.3%) eltrombopag patients versus 6/54 (11.1%) in placebo (odds ratio, 5.9; 95% CI, 2.3 to 14.9; P < .001). In eltrombopag patients, 12/47 (25.5%) lost the PLT-R, with cumulative thrombocytopenia relapse-free survival at 60 months of 63.6% (95% CI, 46.0 to 81.2). Clinically significant bleeding (WHO bleeding score ≥ 2) occurred less frequently in the eltrombopag arm than in the placebo group (incidence rate ratio, 0.54; 95% CI, 0.38 to 0.75; P = .0002). Although no difference in the frequency of grade 1-2 adverse events (AEs) was observed, a higher proportion of eltrombopag patients experienced grade 3-4 AEs (χ2 = 9.5, P = .002). AML evolution and/or disease progression occurred in 17% (for both) of eltrombopag and placebo patients with no difference in survival times. CONCLUSION: Eltrombopag was effective and relatively safe in low-risk MDS with severe thrombocytopenia. This trial is registered with ClinicalTrials.gov identifier: NCT02912208 and EU Clinical Trials Register: EudraCT No. 2010-022890-33.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Oliva EN, Riva M, Niscola P, et al. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). J Clin Oncol. 2023. PMID: 37294914. doi:10.1200/JCO.22.02699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。